Scopolamine

Scopolamine may produce unpredictable and potentially dangerous effects in patients with myasthenia gravis due to interference with cholinergic neuromuscular transmission. While scopolamine acts at muscarinic rather than nicotinic receptors, the overall disruption of cholinergic tone may worsen symptoms.

Elderly patients with cognitive impairment are at substantially elevated risk for anticholinergic-induced delirium. The aging brain has reduced cholinergic reserve, and pre-existing cognitive deficits lower the threshold for delirium. Cumulative anticholinergic burden is also associated with increased dementia risk in this population.

Scopolamine undergoes extensive first-pass hepatic metabolism via CYP3A and glucuronide conjugation. Significant hepatic impairment reduces clearance, increasing systemic exposure and the risk of anticholinergic toxicity. Dose adjustment guidance is not established.

Muscarinic M3 blockade relaxes the detrusor muscle of the bladder, reducing contractile force and increasing residual volume. In patients with pre-existing bladder outlet obstruction (BPH) or urinary retention, scopolamine can precipitate acute urinary retention requiring catheterization.

Renal clearance contributes to scopolamine elimination (4.2 L/hr). Significant renal impairment may reduce elimination of the parent compound and glucuronide metabolites, increasing exposure and toxicity risk.

Patients with known hypersensitivity to scopolamine, atropine, or other belladonna alkaloids should not receive scopolamine in any formulation. Cross-reactivity across the tropane alkaloid class is expected due to the shared tropic acid ester pharmacophore.

Scopolamine may precipitate eclamptic seizures in patients with severe preeclampsia. The mechanism is not fully characterized but may relate to CNS effects or cardiovascular perturbation in an already unstable vascular state. Scopolamine also crosses the placenta.

Children exhibit increased sensitivity to scopolamine's CNS effects. Toxic psychosis with hallucinations, agitation, and bizarre behavior has been reported from application of a single standard transdermal patch in a 4-year-old (Lin et al. 2011). The narrow therapeutic window in pediatric populations makes dosing hazardous.

Scopolamine-induced mydriasis can trigger acute angle-closure glaucoma in anatomically predisposed individuals. This is an absolute contraindication listed in FDA labeling and StatPearls. The mechanism is direct — M3 receptor blockade in the iris sphincter causes pupil dilation, physically narrowing the drainage angle.

Co-administration with other anticholinergic agents — tricyclic antidepressants, first-generation antipsychotics, antihistamines (diphenhydramine, hydroxyzine), bladder antimuscarinics (oxybutynin, tolterodine), antiparkinsonian agents (trihexyphenidyl, benztropine) — produces additive anticholinergic burden with increased risk of toxic delirium, paralytic ileus, and acute urinary retention.

Scopolamine's central sedative effects are additive with other CNS depressants. Opioids deserve specific mention: they possess intrinsic anticholinergic properties, so the combination increases both sedation and peripheral antimuscarinic effects (constipation, urinary retention).

Grapefruit juice increases scopolamine AUC to approximately 142% of control values by inhibiting intestinal CYP3A (Renner 2005). Other potent CYP3A inhibitors (ketoconazole, erythromycin, ritonavir) are expected to produce similar or greater increases in exposure, though specific interaction studies have not been conducted.

The Transderm Scōp transdermal patch contains a metal foil layer that can interact with the radiofrequency fields in MRI, causing localized skin burns at the application site. The patch must be removed before MRI and may be reapplied afterward.